Analyst Kim, along with Chairman & CEO Lin, CFO Chuang and CSO Mata, discuss Tinlarebant Takeaways Post-AAO and ahead of Phase 3 Stargardt Data In Mid-2024 on a conference call to be held on November 9 at 12 pm hosted by Cantor Fitzgerald. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BLTE:
- Belite Bio participates in a conference call with Cantor Fitzgerald
- Belite Bio price target raised to $59 from $55 at H.C. Wainwright
- Belite Bio presents results from a 24-month, Phase 2 study of Tinlarebant
- Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting
